Leerink Swann set a $100.00 price objective on Henry Schein (NASDAQ:HSIC) in a research report sent to investors on Tuesday, August 7th. The firm currently has a buy rating on the stock. Leerink Swann also issued estimates for Henry Schein’s Q3 2018 earnings at $1.01 EPS, Q4 2018 earnings at $1.15 EPS and FY2019 earnings at $4.55 EPS.
Other research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Henry Schein from a buy rating to a hold rating in a report on Thursday, May 10th. BidaskClub raised shares of Henry Schein from a hold rating to a buy rating in a report on Thursday, July 26th. Stifel Nicolaus raised their target price on shares of Henry Schein from $76.00 to $81.00 and gave the stock a hold rating in a report on Tuesday, August 7th. Robert W. Baird raised their target price on shares of Henry Schein from $83.00 to $90.00 and gave the stock an outperform rating in a report on Tuesday, August 7th. Finally, ValuEngine cut shares of Henry Schein from a sell rating to a strong sell rating in a report on Wednesday, May 2nd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $84.11.
NASDAQ:HSIC traded up $0.68 during mid-day trading on Tuesday, hitting $77.68. The stock had a trading volume of 1,388,000 shares, compared to its average volume of 1,620,635. The company has a market capitalization of $12.36 billion, a P/E ratio of 21.58, a price-to-earnings-growth ratio of 2.31 and a beta of 1.00. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.68 and a current ratio of 1.29. Henry Schein has a twelve month low of $62.56 and a twelve month high of $89.34.
In other Henry Schein news, EVP Mark E. Mlotek sold 10,359 shares of the firm’s stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $72.73, for a total value of $753,410.07. Following the sale, the executive vice president now owns 79,506 shares in the company, valued at $5,782,471.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul Brons sold 4,822 shares of Henry Schein stock in a transaction on Monday, June 11th. The stock was sold at an average price of $72.93, for a total transaction of $351,668.46. Following the transaction, the director now owns 20,889 shares in the company, valued at approximately $1,523,434.77. The disclosure for this sale can be found here. Company insiders own 1.15% of the company’s stock.
Several large investors have recently modified their holdings of HSIC. Squar Milner Financial Services LLC acquired a new position in shares of Henry Schein during the second quarter worth $120,000. Piedmont Investment Advisors LLC acquired a new position in shares of Henry Schein during the second quarter worth $130,000. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Henry Schein by 57.1% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock worth $160,000 after purchasing an additional 800 shares during the period. BerganKDV Wealth Management LLC acquired a new position in shares of Henry Schein during the second quarter worth $203,000. Finally, Quest Investment Management LLC acquired a new position in shares of Henry Schein during the second quarter worth $214,000. Institutional investors own 96.65% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Article: Stock Symbols and CUSIP Explained
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.